Study design
Prospective, randomised and doubleblinded controlled clinical trial across 44 centres in Austria, Germany and Switzerland. Patients who had had an out-of-hospital cardiac arrest were randomly assigned to receive either 2 injections of 40 IU vasopressin or 1 mg epinephrine as vasopressor during CPR. If spontaneous circulation was not restored, the patient received additional treatment with epinephrine. Of the 1219 patients that were randomised, 33 were excluded due to missing studydrug codes, 589 were assigned to receive vasopressin and 597 to receive epinephrine. The two groups had similar clinical profiles. Investigators and physicians were unaware of the studydrug assignment unless decoding became necessary for patient management after initial resuscitation. Additional interventions such as sodium bicarbonate, atropine, amiodarone or thrombolysis were used at the discretion of the managing physician. Neurological function in the surviving patients was assessed using a cerebral performance score.
Outcome measures
The primary end point was survival to hospital admission, and the secondary end points were survival to hospital discharge and neurological outcome.
Results
There was no significant difference in the rate of survival to hospital admission between the vasopressin group and the epinephrine group for patients presenting with either ventricular fibrillation (46.2% vs. 43.0%, p=0.48) or pulseless electrical activity (33.7% vs. 30.5%, p=0.65). For patients presenting with asystole, however, those receiving vasopressin were more likely to survive to both hospital admission (29.0% vs. 20.3%, p=0.02) and hospital discharge (4.7% vs. 1.5%, p=0.04). Cerebral performance was similar between the two groups.
For the 732 patients whose spontaneous circulation was not restored by the initial two study drug injections, additional treatment with epinephrine significantly increased the survival rate in the vasopressin group but not in the epinephrine group (hospital admission: 25.7% vs 16.4%, P=0.002 and hospital discharge: 6.2% vs 1.7%, P=0.002). Cerebral performance in the two groups was stated as not significantly different, but the number of patients surviving to be assessed was small (20 in the vasopressin group vs 5 in the epinephrine group of which 8 vs 0 were in a coma/ vegetative state).
Discussion
This was a large study with randomisation of clinically similar groups that were concealed to both investigators and physicians (unless decoding was necessary for the management of a patient in the period after the resuscitation). All patients initially randomised were accounted for at the end of the trial and were treated as equally feasible during the initial resuscitation, whilst allowing for the clinicians' discretion to give additional treatment such as amiodarone or thrombolysis. Post-resuscitation care would have been difficult to standardise, and may have had an impact on the survival to hospital discharge rates.
The results seem impressive for vasopressin used in asystole, as there was a 42% increase in the rate of survival to hospital admission. The authors suggest that vasopressin may be beneficial in asystole due to the extreme ischaemia inevitably present, as vasopressin has been shown to work in severe acidosis where catecholamines are less potent. In refractory cardiac arrest the improved survival rates by using vasopressin with epinephrine fits with a recent pig based study and may be due to a synergistic effect of the two drugs, especially in prolonged ischaemia.
This study did not demonstrate any clinically significant difference in neurological outcome but the numbers surviving were small (especially for those who had additionally received epinephrine, where 50% had severe cerebral disability or were comatose compared to only 20% that received epinephrine alone). There may well have been more survivors using vasopressin, but what level of cerebral functioning and quality of life will they have? I feel that larger groups are needed before we can say for definite that cerebral outcome is not affected. The implications for the patient, and indeed the increased cost of care if there was poor cerebral outcome, are substantial.
Another issue that would need to be resolved if vasopressin is to be introduced into CPR protocols is that prefilled vasopressin syringes are not currently available in the UK and the preparation that is available needs to be stored at 2-8 oC and costs £35 for 40 IU. This would prevent it being included in many emergency drug boxes across the hospital unless refrigeration was available. There is a preparation available in America that can be stored at room temperature that may in the future be licensed in the UK.
Overall, whilst vasopressin may well have an important role to play in cardiopulmonary resuscitation, I feel that we need to ensure that this isn't at the cost of significant impairment of cerebral performance. s Background The use of heparin to prevent clotting of the extracorporeal circuit during continuous renal replacement therapy is associated with an increased risk of haemorrhage 1 . Regional anticoagulation of the circuit with citrate may reduce this risk 2-4 . Citrate, infused proximal to the haemofilter, chelates ionised calcium and prevents circuit clotting. Systemic anticoagulation is prevented by restoring serum ionised calcium by intravenous infusion. Potential adverse effects include systemic hypocalcaemia, hypernatraemia (citrate as the trisodium salt) and metabolic alkalosis (nonfiltered citrate is metabolised to bicarbonate).
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The aim of this study was to compare the safety and efficacy of regional citrate anticoagulation with standard heparin anticoagulation.
Abstract
This study was a single-centre, prospective, non-blinded, randomised crossover trial of citrate vs. heparin in continuous venovenous haemofiltration (CVVH). The study group comprised vasopressor dependent, mechanically ventilated patients who developed acute renal failure and required continuous renal replacement therapy. CVVH was chosen in preference to daily dialysis in these patients because of haemodynamic instability. Exclusion criteria included those with a high risk of bleeding (recent surgery, severe coagulopathy and liver cirrhosis).
Size of study
Forty-seven patients received CVVH over the one year study period, of whom twenty patients were enrolled in the trial. The remainder were excluded on the above criteria.
Intervention
On commencing the first run of CVVH, patients were randomised to receive either heparin or citrate. Subsequent filters were run with the alternate protocol. Crossover continued up to a maximum of four circuits for each patient. Heparin was administered to achieve an activated partial thromboplastin time of 60-80s. The citrate group followed a sliding scale of trisodium citrate and calcium chloride infusions to maintain circuit ionised calcium < 0.3mmol/l and serum ionised calcium within the normal range.
Outcomes
The primary end point was time to failure of the haemofilter. Secondary end points were transfusion requirements, incidence of major bleeding and metabolic complications.
